Executive Sales Dominate as Insider Activity Turns Bearish Despite CEO Buy
Insider trading activity showed a strong bearish bias, with $40.1 million in net sales recorded over the past 12 hours, led by Best Buy’s Chairman Emeritus disposing of $27.75 million and United Therapeutics’ CEO and EVP selling $8.8 million combined. Only Landstar’s CEO made a notable purchase of $714,619, standing out as a rare bullish signal amid widespread selling.
Over the past 12 hours on November 2, 2026, insider trading activity revealed a pronounced bearish trend, with $40.1 million in net sales recorded across 20 reported transactions—16 sales versus only 4 purchases. The most significant transaction was by Richard M. Schulze, Best Buy’s Chairman Emeritus, who offloaded shares worth $27.75 million, marking the largest single sale of the period. This move came amid broader selling at United Therapeutics (UTHR), where CEO Martine A. Rothblatt sold $4.71 million and EVP Paul A. Mahon disposed of $4.1 million on the same day, totaling $8.8 million in executive-level sales. Other notable sell-offs included Walmart’s CEO John R. Furner ($1.4M), Tidewater director Robert Robotti ($925K), and two Fastly executives—Principal Accounting Officer Jeffrey Ford and Go-to-Market President Scott Lovett—collectively shedding over $1.7 million. In contrast, only three CEOs made open-market purchases: Landstar’s Frank A. Lonegro ($714,619), Ribbon Communications’ Bruce McClelland ($96,240), and API’s CEO (amount unspecified), collectively signaling cautious optimism despite the broader sell-off. The pattern suggests that while some executives see value in their companies, a significant number of insiders—particularly at high-profile firms—are reducing exposure.
The background to this activity includes prior reports of rising macroeconomic uncertainty and sector-specific pressures, especially in tech and healthcare, where growth expectations have co
The recent surge in insider selling—particularly at prominent firms like United Therapeutics and Best Buy—could signal growing caution among corporate leadership, potentially influencing investor sentiment across sectors. While individual sales may stem from personal financial planning, the clustering of high-level transactions raises red flags for retail investors and fund managers who often interpret such moves as early indicators of company-specific or macroeconomic risks. The fact that multiple CEOs sold simultaneously at Fastly and United Therapeutics may amplify market skepticism toward growth-stage tech and biotech stocks, potentially triggering broader profit-taking in those sectors. Conversely, the isolated purchases by Landstar and Ribbon’s CEOs could serve as counterweights, reinforcing confidence in select mid-cap and niche players. A comparable case is the 2018 insider sell-off at Tesla, where multiple executives exited shares amid rising scrutiny over valuation and execut